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Abstract
Tryptophan (Trp) catabolism into immunosuppressive kynurenine (Kyn) by indoleamine 2,3-dioxygenase (IDO) was
previously linked to Th17/Treg differentiation and immune activation. Here we examined Trp catabolism and its
impact on Th17/Treg balance in uninfected healthy subjects (HS) and a large cohort of HIV-infected patients with
different clinical outcomes: ART-naïve, Successfully Treated (ST), and elite controllers (EC). In ART-naïve patients,
increased IDO activity/expression, together with elevated levels of TNF-α and sCD40L, were associated with Treg
expansion and an altered Th17/Treg balance. These alterations were normalized under ART. In contrast, Trp 2,3-
dioxegenase (TDO) expression was dramatically lower in EC when compared to all other groups. Interestingly, EC
displayed a distinctive Trp metabolism characterized by low Trp plasma levels similar to ART-naïve patients without
accumulating immunosuppressive Kyn levels which was accompanied by a preserved Th17/Treg balance. These
results suggest a distinctive Trp catabolism and Th17/Treg balance in HIV progressors and EC. Thus, IDO-induced
immune-metabolism may be considered as a new inflammation-related marker for HIV-1 disease progression.
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Introduction
Chronic HIV-1 infection is characterized by progressive
depletion of total CD4+ T-cells and persistent immune
activation, events that are only partially controlled by
antiretroviral therapy (ART). Immune activation is associated
with increased production of inflammatory soluble factors,
further contributing to immune dysfunction [1]. Immune
stimulators including interferon (IFN)γ [2], cytotoxic T-
lymphocyte antigen-4 (CTLA-4) ligation [3] and Toll-like
receptor (TLR) stimulation [4] induce intracellular indoleamine
2,3-dioxygenase (IDO) by macrophages and dendritic cells
(DCs) [5,6]. IDO catabolizes the essential amino acid
Tryptophan (Trp) into an immunosuppressive metabolite,
Kynurenine (Kyn), that limits immune responses in cancers and
chronic viral infections and/or induces immune tolerance during
pregnancy[5-11]. Another enzyme that catabolizes Trp is
Tryptophan 2,3-dioxygenase (TDO) which is mainly expressed
in the liver as well as other tissues including the brain, uterus
and skin [12-15].
Among T-cell subsets, regulatory T-cells (Tregs), play a
pivotal role in peripheral tolerance and pathogenesis of cancer
and chronic viral infections [16]. Indeed, Tregs were shown to
suppress effector T-cells activation and function [17]. Forkhead
box P3 (FoxP3), the master regulator of Treg function, can
influence the balance between Treg and T-helper 17 (Th17)
cells. Th17 cells play a critical role in maintaining the integrity
of mucosal immunity against pathogens [18-21]. HIV-1 infection
is characterized by a rapid Th17 cell depletion associated with
an expansion of Tregs owing to cellular immune activation
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and/or low CD4+ T-cell counts [18,19]. The impaired Th17/Treg
balance in HIV-1 infection has a deleterious effect on gut
mucosal immunity and fuels immune activation by enhancing
microbial translocation [9,22,23]. It has been recently shown
that IDO-induced Trp catabolism promotes T-cell differentiation
into Treg versus Th17 cells through FoxP3 over-expression
[9,24,25]. Importantly, for both Simian immunodeficiency virus
(SIV) and HIV-1 infections, the altered Th17/Treg balance in
blood and mucosal tissues is directly linked to a sustained
increase of IDO activity via IFN-γ signaling and TLR ligation
[2,18]. Findings by Favre et al. in HIV-infected subjects indicate
that elevated IDO activity is associated with enhanced
microbial translocation and faster disease progression [2,18].
Herein, we assessed IDO-induced Trp catabolism in relation
with Th17/Treg balance in the largest cohort of HIV-infected
patients ever studied in this context, including a remarkable
subset of patients called elite controllers (EC) who achieve
long-term control of viremia and disease progression in the
absence of ART [26]. Our results provide evidence that IDO-
induced Trp catabolism into Kyn induces a harmful effect on
the Th17/Treg ratio that may subsequently contribute to
enhanced microbial translocation during HIV-1 infection.
Importantly, EC compared to ART-Successfully Treated (ST)
and healthy subjects (HS) displayed a distinctive Trp
catabolism characterized by similar Kyn/Trp ratios despite
significantly lower plasma Trp levels, dramatically reduced
TDO expression, and preserved IDO expression and Th17/
Treg ratios. Thus, new therapeutic interventions modulating the
IDO-mediated Trp catabolism may help limit disease
progression in HIV-infected subjects.
Materials and Methods
Study population
Peripheral blood mononuclear cells (PBMC) and plasma
were collected from untreated ART-naïve patients (n=96), ART-
successfully treated (ST, n=88) and healthy subjects (HS,
n=50) at the Chronic Viral Illness Service, McGill University
Health Centre (MUHC), Montreal, QC, Canada. Samples from
elite controllers (EC) (n=19) were obtained from the FRQ-S
slow progressor cohort, Montreal, QC, Canada (Table 1). To
avoid the influence of other factors that could modulate Trp
levels, all subjects were accounted for seasonal variation and
nutritional status (body mass index, albumin and cholesterol
levels) [27,28]. Plasma levels of Trp, Kyn and 3-
Hydroxykynurenine (3OH-Kyn) were measured in all 253
subjects. Levels of inflammatory markers, sCD14, Treg and
Th17 cell frequency, IDO-1, IDO-2 and TDO mRNA expression
were evaluated in a random subset of n=14 per study group.
Ethics statement
This study, using PBMC and plasma samples from HIV-
infected and uninfected subjects, was conducted in compliance
with the principles included in the Declaration of Helsinki. This
study received approval from the Ethical Review Board of the
McGill University Health Center, Montreal, Canada. All blood
donors provided written informed consent of their participation
to the study.
Measurement of the plasma concentration of
Tryptophan and its catabolites
Plasma levels of Trp, Kyn and 3OH-Kyn were measured by
an automated on-line solid-phase extraction-liquid
chromatographic-tandem mass spectrometric (XLC-MS/MS)
method as previously reported [29]. Briefly 250μL plasma was
Table 1. Clinical and virological characteristics of study groups.
Characteristics Study population N=253
 ST (n=88) ART- naïve (n=96) EC (n=19) HS (n=50)
Age (years) [Mean ± SD (range)] 48.4±9.4 (29-81) 39.2±9.2 (23-58) 49.0±7.1 (40-62) 45.0±9.9 (19-64)
Male [n (%)] 73 (83%) 76 (79%) 9 (47%) 35 (70%)
Risk factors:     
Men Who Have Sex with Men [n (%)] 59 (67%) 58 (60%) 6 (32%) NA
Heterosexual [n (%)] 15 (17%) 22 (23%) 10 (53%) NA
Endemic [n (%)] 11 (13%) 12 (13%) 2 (11%) NA
Injection drug users [n (%)] 3 (3%) 4 (4%) 1 (5%) NA
Time since HIV-1 diagnosis (years) [Mean ± SD (range)] 10.1±5.5 (2-24) 4.2±5.2 (0-23) 13.1±4.1 (4-20) NA
CD4 T-cell count (cells/µL) [Mean ± SD range)] 531.3±267.4 (37-1282) 416.1±189.2 (3-1110) 617.8±209.4 (417-1341) 812.6±273.0(281-1559)
CD8 T-cell count (cells/µL)[Mean ± SD (range)] 785.8±332.6 (153-2013) 761.9±365.2 (237-1933) 559.7±307.0 (162-1198) 390.9±188.5 (95-843)
CD4:CD8 ratio [Mean ±SD (range)] 0.75±0.42 (0.08-2.06) 0.64±0.38 (0.01-12.09) 1.35±0.61 (0.35-2.72) 2.45±0.96 (0.38-4.34)
VL (log10copies/mL) [Mean ±SD (range)] < 1.6 4.0±0.87 (1.73-6.35) < 1.6 NA
Time of undetectable VL (years)[Mean ± SD (range)] 3.64±2.7 (1-10) NA 12.8±7.0 (7-20) NA
Time since start of ART (years) [Mean ± SD (range)] 8.1±4.7 (1-20) NA NA NA
These include ART-successfully treated (ST), ART-naïve, Elite controllers (EC) and Healthy subjects (HS). Results are shown as mean ± standard deviation (SD) and
(Range), NA: not applicable, VL: Viral Load.
doi: 10.1371/journal.pone.0078146.t001
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mixed with 50 μL deuterated internal standard working solution
(300 μmol/L in diluted acetic acid for Trp and 5 μmol/L for Kyn
and 3OH-Kyn) and diluted with 200 μL water. The samples
were placed into the autosampler, which picks up 50μL of the
sample leading it to the solid-phase extraction chromatography
(SPE) cartridge. The sample was washed on the SPE cartridge
where the washed cartridge extract was eluted into the high-
performance liquid chromatography (HPLC) column. The
binary gradient system consisted of mobile phase A (0.2%
formic acid in water) and mobile phase B (acetonitrile). During
this step, chromatographic procedure separated Trp, Kyn and
3OH-Kyn. The HPLC column effluent was then led into a mass
spectrometer operated in positive ionization MRM mode to
protonate the ions, and quantitatively detect selected masses.
Finally, to quantify the amino acid metabolites, the area of
specific mass peaks was measured and related to
concentration of calibration curves of the respective
metabolites.
In vitro characterization of Th17 cells
PBMCs were thawed in a 37°C water bath and cultured in
48-well culture plates at 0.5-1 × 106 cells/mL per well. These
assays were performed with no stimulation as a negative
control or stimulation with PMA (50 ng/mL) and ionomycin (1
μg/ml) for 2 hours at 37°C and 5% CO2. BFA (2 μg/ml) was
then added to block cytokine secretion and cells were kept in
culture for 18 hours at 37°C and 5% CO2.. The following day,
the cells were transferred into FACS tubes, centrifuged at
1500rpm for 5 minutes and stained for detection of IL-17A.
IFNγ staining was used as a positive control for the assay since
it is highly expressed by T-lymphocytes. PBMCs underwent
surface staining for 20 minutes at 4°C. Cells were fixed using
Cytofix/CytoPerm for 20 minutes at 4°C following
permeabilization using Perm/Wash 1X subsequentl to
intracellular staining with IL-17A and IFNγ at 4°C for 30
minutes. Excess antibody was removed by washing with Perm/
Wash 1X following a final wash with FACS buffer before flow
cytometry acquisition.
Flow cytometry
Detection of surface and intracellular markers was performed
by a four-laser LSRII flow cytometer (BD Bioscience,
Mississauga, ON, CA). The following Abs were used: CD3-
Pacific blue, CD4-PercpCy5.5, CD4-PECy5, CD8-Alexa700,
CD25-PE, CD127-PECy7, CD38-APC, and IFN-γ-Alexa700
(BD Bioscience, Mississauga, Ontario, CA); CD45RA-ECD was
from Beckman Coulter (Mississauga, Ontario, CA) and IL-17-
PE, CD8-APCeFluor780 and FOXP3Alexa488 were from
eBioscience (San Diego, USA). Magnetic beads coated with
anti-rat and anti-mouse Abs were used as positive/negative
controls for compensation calculation (BD Bioscience,
Mississauga, Ontario, CA). The viability marker Vivid AmCyan
(Invitrogen, Burlington, Ontario, CA) was used to exclude dead
cells from analysis. Data was exported and analyzed using
FlowJo software v7.6.5. Tregs were characterized as
CD3+CD4+CD25highCD127lowFoxP3high and Th17 cells as
CD3+CD4+IL-17a+ upon PMA/ionomycin stimulation.
Quantification of IDO-1, IDO-2 and TDO mRNA
Total RNA from PBMCs were extracted with RNeasymini kits
(Qiagen, Hilden, Germany). cDNA was synthesized from total
RNA (500 ng) with oligo-dT and random hexamer primers
(Applied Biosystems, Carlsbad, CA, USA), using an Omniscript
reverse transcriptase kit (Qiagen). Then, specific mRNAs were






CAGTTGATCGCAGGTAGTGATAG), 18s ribosomal RNA
(forward: ATCAACTTTCGATGGTAGTCG; revers:
TCCTTGGATGTGGTAGCCG). Quantitative real-time RT-PCR
was performed by Rotorgene 3000 thermal cycler (Corbett Life
Science, Sydney, Australia) and Quantitect Sybr Green PCR kit
(Qiagen). The cycling conditions were 10 min at 95°C, then 35
cycles of 30s at 94°C, 45s at 60°C, and 30s at 72°C for 18s
rRNA. For IDO-1, IDO-2, and TDO amplifications, 40 cycles
were performed with 60s annealing at 55°C, 52°C, and 56°C,
respectively, followed by 30s at 72°C. A ﬁnal melting curve was
obtained from 72 to 95°C. The expression of each gene was
quantified relative to the housekeeping gene 18s rRNA.
Measurement of plasma levels of sCD14 and IL-6
Plasma levels of sCD14, as well as IL-6 were measured
using commercially available human sCD14 and IL-6 ELISA
kits (both from R&D systems Minneapolis, MN, USA),
according to the manufacturer’s instructions.
Multiplex quantification of inflammatory plasmatic
cytokines
Prior to analysis, all plasma samples were treated 10:1 with
5% TritonX-100 for one hour in order to inactivate the HIV-1
virus. Plasma levels of selected soluble factors implicated in
IDO induction, including IFNγ, TNF-α, IL-1β and sCD40L were
measured in duplicates using a MILLIPLEX MAP magnetic
bead kit according to the manufacturer’s instructions (Millipore,
Billerica, MA, USA). A broad range of standards were run in
duplicates along with quality controls provided by the
manufacturer to ensure the proper functioning of the kit. Mean
fluorescence intensities for each analyte in each sample were
detected using the MAGPIX instrument (Luminex) and the
results were analyzed using the Millipore Analyst software
version 3.5.5 to obtain the protein concentration of each
soluble factor.
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software version 5. One-way ANOVA or Kruskal-Wallis tests
were performed for comparisons between study groups
according to the sample size. Unpaired t-tests or Mann-
Whitney U tests were used for comparison of two non-paired
study variables according to the sample size. The Pearson
rank correlation test was used to identify association amongst
Tryptophan Catabolism in HIV-Infection
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study variables. All results are presented in Mean±SD
throughout the manuscript.
Results
Plasma concentrations of Trp and its catabolites in HIV-
infected patients with different clinical outcomes
It has been shown by Favre et al. that increased IDO activity
affects T-cell function and is linked to HIV-1 disease
progression [2]. To confirm and expand these findings, plasma
levels of Trp and its key catabolites, Kyn and 3OH-Kyn, were
measured in 253 study subjects.
ART-naïve compared to ST and HS demonstrated
significantly lower Trp levels (ART- naïve 46.60±11.24 vs. ST:
52.39±11.62 and HS: 54.46±12.68 μmol/L; Figure 1A). In
contrast, EC who spontaneously control viral load (VL) in
absence of ART had comparable Trp levels to ART-naïve
subjects (47.40±14.45 μmol/L). Levels of the Trp catabolite Kyn
were significantly elevated in ART-naïve subjects compared to
all other groups (ART-naïve: 2.37±0.76 vs. ST: 2.08±0.91, EC:
1.74±0.36, HS: 1.72±0.44 μmol/L; Figure 1B). Similar results
were obtained for the Kyn byproduct 3OH-Kyn (ART-naïve:
50.96±26.09, ST: 39.26±33.49, EC: 37.84±14.37 and HS:
39.24±11.84 nmol/L; Figure 1C). Correspondingly, IDO enzyme
activity (Kyn/Trp ratio) was also elevated in ART-naïve subjects
compared to all other groups (ART-naïve: 0.054±0.026 vs. ST:
0.041±0.018, EC: 0.039±0.011, HS: 0.033±0.010 μmol/L;
Figure 1D). By contrast, EC maintained comparable levels of
Trp catabolites and IDO activity when compared to ST and HS
possibly suggesting a particular Trp catabolism in these
patients, which may be related to their spontaneous ability to
control viral replication. No significant difference was observed
in Trp, Kyn and 3OH-Kyn levels between EC with or without
protective HLA alleles, HLA B57 and B27[30] (p>0.05 for all
comparisons, data not shown).
In ART-naïve patients, while Trp levels were not associated
with VL, levels of Kyn, 3OH-Kyn and IDO enzymatic activity
(Kyn/Trp ratio) were positively correlated with plasma VL
(Figure 2A-D). Absence of correlation was observed between
Trp and CD4+ T cell counts whereas Kyn, as well as the
Kyn/Trp ratio, were negatively correlated with CD4+ T-cell
counts (Figure 2E-G).
IDO enzymatic activity and its impact on Th17/Treg
imbalance in HIV-1 infection
A decreased Th17/Treg ratio has been previously associated
with elevated plasma Trp catabolites in HIV-infected patients
[2]. We therefore examined the expression of these T-cell
subsets in the peripheral blood in each study group. Our results
showed a trend towards decreased Th17 frequency in ART-
naïve subjects compared to all other groups, (ART-naïve:
0.337±0.406% vs. ST: 0.512±0.424%; EC: 0.486±0.346% and
HS: 0.510±0.580%). However, statistical significance was not
reached between groups (Figure 3A). In contrast, the Treg
frequency was significantly increased in ART-naïve patients
compared to all other groups (ART-naïve; 5.13±1.82% vs. ST;
3.12±0.84% EC; 3.31±1.17% and HS; 3.20±1.22%; Figure 3B).
Consequently, ART-naïve subjects exhibited the lowest Th17/
Treg ratios compared to all other groups (ART-naïve:
0.062±0.052 vs. ST: 0.161±0.115 EC: 0.150±0.104 and HS:
1.3±0.10; Figure 3C). Notably, Th17/Treg ratios in EC and ST
were comparable to those in HS (Figure 3C).
Moreover, IDO is a critical molecule, which stimulates Tregs
while blocking the reprogramming of Tregs into Th17 [9,25].
Our results showed IDO enzymatic activity (Kyn/Trp ratio) was
associated with Th17/Treg ratio (Figure 3D) as well as with
Treg frequency (Figure 3E). As sCD14 has been shown to be a
reliable marker of microbial translocation [23], we showed that
the imbalance of Th17/Treg was inversely correlated to
elevated plasmatic sCD14 (Figure 3F).
mRNA expression of the Trp catabolizing enzymes
IDO-1, IDO-2 and TDO in HIV-infected patients
To further investigate the molecular basis for increased IDO
enzymatic activity, we quantified IDO-1 and IDO-2 mRNA
relative expression in PBMCs. ART-naïve patients
demonstrated significantly higher levels of IDO-1 mRNA
expression, compared to ST, EC and HS (0.113±0.124 vs.
0.015±0.018, 0.033±0.043 and 0.056±0.049). Interestingly, EC
exhibited IDO-1 mRNA levels comparable to HS and ST
(Figure 4A). In addition to IDO-1, we also evaluated levels of
IDO-2 mRNA, another enzyme responsible for Trp catabolism
into Kyn but expressed in different cell subsets suggesting
these enzymes are not functionally redundant [31]. Unlike
IDO-1 expression, IDO-2 mRNA relative expression was
unchanged between study groups (ST: 0.061±0.155, ART-
naïve: 0.098±0.281, EC: 0.065±0.245 and HS: 0.065±0.238,
p>0.05 for all comparisons; data not shown).
Another enzyme, TDO, regulates systemic Trp [12]. Our
results demonstrated that levels of TDO were dramatically
lower in EC when compared to all other groups (EC:
0.0005±0.001 vs. ST: 0.529±0.986, ART-naïve: 0.618±0.834
and HS: 0.030±0.082). Of note, TDO levels were also
significantly lower in HS when compared to ART-naïve subjects
and to ST (Figure 4B). Our results also showed a trend
between TDO mRNA expression and Kyn/Trp ratios when
evaluated in all study subjects (p=0.06, R=0.261, data not
shown). Such a correlation was not observed when evaluated
in each study group separately (p>0.05 for all comparisons,
data not shown).
We then studied the correlation between IDO-1 and TDO
mRNA levels with plasma HIV-RNA VL and CD4+ T-cell counts
in ART-naïve subjects. We found a trend for a positive
correlation between IDO-1 mRNA and plasma VL (p=0.0761,
R=0.4714; data not shown). In contrast, IDO-1 mRNA
expression was negatively correlated with CD4+ T-cell count in
ART-naïve subjects (p=0.0051, R=-0.6821; data not shown).
No correlation was fond between TDO expression and VL and
CD4+ T-cell count (not shown). We also observed a positive
association between Treg frequency and IDO-1 mRNA
expression (Figure 4C).
IDO enzymatic activity is associated with elevated
levels of TNF-α and sCD40L in HIV-infected patients
In cancer patients, inflammatory changes indicate that IDO
may be induced by soluble factors including IFNγ, TNF-α,
Tryptophan Catabolism in HIV-Infection
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IL-1β, soluble CD40 ligand (sCD40L) and CTLA-4 ligation to
CD80/CD86 expressed by DC [5,32,33]. In vitro stimulation of
DCs by IFNγ promotes IDO-1 while IL-1β, IL-6, and TNF-α
enhance IFNγ ability to promote IDO-activity [2].
sCD40L plasma levels were significantly higher in ART-naïve
subjects compared to ST (Table 2). In contrast, EC had similar
sCD40L levels compared to ST. Levels of IFN-γ and TNF-α
were significantly elevated in ART-naïve subjects compared to
EC (Table 2). Moreover, IL-6 was significantly higher in ART-
naïve patients compared to all other groups. Interestingly,
among the soluble factors implicated in IDO induction, sCD40L
and TNF-α as well as IL-6, but not IL-1β and IFNγ, were
positively correlated to elevated IDO enzymatic activity when
evaluated in all study subjects (Figure 5). Such a correlation
between soluble factors and IDO activity was only observed for
sCD40L in ART-naïve patients (p=0.0270, R=0.5880) as well
Figure 1.  Tryptophan catabolism is elevated in HIV-infected subjects with disease progression but not elite
controllers.  Plasma levels of (A) tryptophan (Trp), (B) kynurenine (Kyn), (C) and 3 -hydroxykynurenine were measured by XLC-
MS/MS in ART-successfully treated (ST, n=88), ART-naïve (n=96), elite controllers (EC, n=19), and healthy subjects (HS, n=50),
(D) IDO activity in shown, defined as the Kyn/Trp ratio. Statistical analysis was provided by ANOVA tests followed by unpaired t-
tests used for comparison of two variables.
doi: 10.1371/journal.pone.0078146.g001
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Figure 2.  Tryptophan catabolites are associated with higher HIV-1 viral load (VL) and lower CD4+ T-cell counts in ART-
naïve patients.  Association between plasmatic HIV-1 viral load and plasmatic (A) tryptophan (Trp) (B) kynurenine (Kyn) (C) 3-
hydroxykynurenine (3OH-Kyn) and (D) IDO activity as defined by Kyn/Trp and CD4+ T-cell counts and plasmatic (E) tryptophan (F)
kynurenine (G) 3-hydroxykynurenine and (H) IDO activity (Kyn/Trp ratio) in ART-naïve patients (n=96). Pearson rank correlation was
used for statistical analysis.
doi: 10.1371/journal.pone.0078146.g002
Tryptophan Catabolism in HIV-Infection
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Figure 3.  Th17/Treg imbalance in HIV-1 infection correlates with IDO enzyme activity.  (A) Th17 cells (CD4+IL-17+) frequency
in study groups following PMA/Ionomycine in vitro Stimulation (B) Frequency of Treg (CD4+CD25highCD127lowFoxP3high cells) in study
groups ex vivo . (C) Th17/Treg ratio in study groups. (C) Th17/Treg ratio in study groups. (D) Correlation between IDO enzymatic
activity defined by Trp/Kyn ratio and Th17/Treg ratio in study groups. (E) Association between IDO enzymatic activity and Treg
frequency in study groups. (F) Correlation between bacterial translocation marker sCD14 and Th17/Treg ratio in study groups. ST:
ART-successfully treated, ART-naïve, EC: elite controllers, and HS: healthy subjects. n=14 per study group. Statistical analysis was
provided by Kruskal-Wallis test followed by Mann-Whitney U test for comparison of two variables.
doi: 10.1371/journal.pone.0078146.g003
Tryptophan Catabolism in HIV-Infection
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as HS (p=0.0435, R=-0.5457) and for IL-6 in EC (p=0.0090,
R=0.6684) when evaluated in each study group separately
(Table S1). A similar positive correlation was also observed
between plasma sCD40L, TNF-α and IL-6 levels and levels of
IDO-1 mRNA expression when evaluated in all study subjects
(p=0.0015, R=0.4289; p=0.03, R=0.2969 and p<0.0001,
R=0.5939 respectively; Table S2). Such a correlation between
soluble factors and IDO-1 mRNA expression was only
observed for sCD40L and IL-6 in the ART-naïve group when
evaluated in each study group separately (p=0.0175, R=0.6223
and p=0.0181, R=0.6196 respectively; Table S2).
Discussion
Numerous studies provided evidence for an association
between HIV disease progression and increased plasma levels
of inflammatory factors such as IDO-induced Trp catabolism
[1,2,34]. IDO catabolizes Trp into Kyn and is involved in control
of inflammatory signals providing protection for tissue damage
and inducing immune tolerance [5,6]. The Trp catabolite Kyn
has immunosuppressive properties suppressing T-cell
functions and proliferation [7,35]. In this study, we evaluated
Trp levels and its catabolites in a well-defined cohort of HIV-
Figure 4.  Trp catabolizing enzyme IDO-1 mRNA expression is associated with Treg frequency in HIV-1 infected patients
with different clinical outcomes.  (A) Real-time quantitative RT-PCR was used to quantify IDO-1 mRNA and (B) TDO expression
relative to the 18s ribosomal RNA from PBMCs of study groups. (C) Association between IDO enzymatic activity and Treg
frequency in study groups. ST: ART-successfully treated, ART-naïve, EC: elite controllers, and HS: healthy subjects. N=14 per
study group. Statistical analysis was provided by Kruskal-Wallis test followed by Mann-Whitney U test for comparison of two
variables. Pearson rank test was used for the correlation.
doi: 10.1371/journal.pone.0078146.g004
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infected patients with different clinical outcomes. Trp levels
were significantly decreased in HIV-infected adults whose
infection was uncontrolled (ART-naïve subjects) when
compared to those whose infection was successfully controlled
pharmacologically or who were uninfected confirming prior
reports [10,11]. ART-naïve also demonstrated the highest
levels of Kyn, its byproduct (3OH-Kyn), and IDO enzymatic
activity (Trp/Kyn ratio). In contrast, levels of Trp catabolites
declined in ART-treated subjects as did IDO enzymatic activity.
In addition, Trp catabolites and Kyn/Trp ratio were associated
with both elevated plasma viral load and low CD4+ T-cell
counts. Thus, ART normalized Trp catabolism in HIV-infected
subjects by reducing IDO enzymatic activity. It is of interest that
increased Trp catabolism in HIV infection is implicated in
neuropathology [36] and disease progression [34].
EC constitute a minority of HIV-infected patients that are able
to control viral replication and preserve CD4+ T-cell counts
over time in the absence of ART [26]. EC have efficient
immune responses and activation linked in part to HLA genetic
determinism [26,37]. In SIV infection, SIV controllers display
much lower IDO expression in blood, lymph nodes and gut
associated lymphoid tissues as compared to pathogenic SIV-
infection [38,39]. Interestingly, our results demonstrate that Trp
levels were similarly low in EC and ART-naïve subjects
whereas levels of Trp catabolites and Kyn/Trp ratio were
significantly lower and were similar to those found in ST or HS.
IDO expression can be triggered by Forkhead box O3 (FOXO3)
via induction of superoxide dismutase and blockade of
peroxynitrite formation [40]. Thus, silencing FOXO3a
expression inhibits Trp catabolism mediated by CTLA-4-Ig [41].
Furthermore, down-regulation of FOXO3a transcriptional
activity in EC represents a molecular signature which can help
protect survival of memory T-cells and slow disease
progression [42,43]. Our findings suggest a link between
distinctive Trp catabolism in EC and a consistently lower
FOXO3a expression and IDO activity in these patients. Our
results showed no difference in Trp, Kyn and 3OH-Kyn levels
between EC with or without protective HLA alleles B57 and
B27, indicating that mechanisms other than those governed by
the adaptive immunity are regulating Trp catabolism in EC.
Altogether, we have observed a distinctive pattern of Trp
catabolism in EC; whereby they do not seem to accumulate
immunosuppressive Trp catabolites and do not progresses to
immune dysfunction or tolerance. While unexplained, these
changes suggest a new avenue for HIV control.
The Th17/Treg balance plays a dominant role in the
maintenance of mucosal immunity [9,16]. These cells are
derived from common progenitor cells and their differentiation
pathways are reciprocally modulated upon immune activation
during HIV-1 infection, resulting in bacterial translocation
[9,18,20,21]. We observed a lower Th17/Treg ratio in ART-
naïve subjects when compared to the other study groups. This
was associated with a lower Th17 frequency and an
enrichment of Treg frequency, together with higher levels of
microbial translocation marker sCD14. One potential
explanation is that Trp catabolites induce Tregs and reduce the
generation of Th17 cells [2,9,24,25]. Our results also show
such a relationship where IDO enzymatic activity (Kyn/Trp
ratio) was associated with a decrease in Th17/Treg ratio,
driven mainly by an increase in Treg frequency. This suggests
that the immunomodulatory enzyme IDO, through its Trp
deprivation and/or an increase in its immunosuppressive
catabolites, may be an important pathway that can maintain
chronic inflammation in HIV-1 infection.
Moreover, we found that IDO-1 mRNA expression was
significantly increased in ART-naïve subjects and was
associated with elevated viral load, low CD4+ T-cell count and
importantly elevated Treg frequency. We also evaluated IDO-2
enzyme mRNA expression which is also expressed in antigen-
presenting cells (not as widely expressed as IDO-1) and
catabolizes the same enzymatic step as IDO-1 [31]. We
observed slightly lower levels of IDO-1 mRNA expression in
total PBMCs from ST and EC compared to HS possibly due to
a redistribution of DCs, the main producers of IDO-1, into
lymphoid tissues in HIV-infected patients. Thus, quantification
of IDO-1 mRNA in the FACS-sorted leucocyte populations may
help to better evaluate the nature of these changes. Unlike the
changes in IDO-1 expression, IDO-2 mRNA expression was
not different between study groups, thus highlighting the pivotal
immunosuppressive role of IDO-1 in HIV-1 infection. TDO,
expressed mostly by the liver and also by the brain, uterus, and
skin, is responsible for regulating systemic Trp [12-15]. TDO
expression is constitutively increased in Alzheimer's disease
[44] and various human tumors and is equally capable of
suppressing antitumor immune responses [13,45]. Our results
showed that ART-naïve and ST patients have significantly
higher TDO mRNA expression when compared to HS. TDO
was not fully suppressed in ST subjects compared to ART-
naïve, possibly because unlike IDO-1 and IDO-2, TDO seems
to be a constitutively expressed gene; therefore, it is not
Table 2. Levels of inflammatory soluble factors in HIV-infected patients with different clinical outcomes.
 ST ART-naive EC HS p value
IL-1β (pg/ml) 2.644±1.777 1.546±0.4678 1.516±0.4909 3.410±1.876 0.1225
IFN-γ (pg/ml) 9.239±2.979 18.670±5.822 5.172±1.269 30.86±16.37 0.0224
sCD40L (pg/ml) 502.7±167.2 1305.0±234.0 968.7±252.4 601.3±173.8 0.0127
TNF-α (pg/ml) 22.01±11.53 29.94±5.93 9.18±2.08 7.67±1.08 0.0008
IL-6 (pg/ml) 0.5807±0.2033 8.0930±5.0010 1.3360±0.7890 9.7060±5.9110 0.0034
Plasma levels of inflammatory soluble factors IL-1β, IFN-γ, sCD40L, TNF-α and IL-6 were measured by Multiplex are shown in Mean±SD pg/ml. Kruskall-Wallis test was
used for statistical analysis. ST: ART-successfully treated, ART-naive, EC: elite controllers, and HS: healthy subjects. n=14 per study group.
doi: 10.1371/journal.pone.0078146.t002
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induced or regulated by immune system signals [46].
Interestingly, levels of TDO were dramatically lower in EC
compared to other study groups. Since TDO is mostly a hepatic
enzyme, it may not account for Trp depletion observed in EC
as this may potentially be mediated by other members of
indolamine dioxygenase superfamily such as PrnB (the second
Figure 5.  Correlations between IDO enzymatic activity and levels of inflammatory soluble factors implicated in IDO
induction.  Associations between IDO activity (Kyn/Trp ratio) and plasmatic levels of (A) IL-1β (B) IFNγ (C) sCD40L (D) TNF-α and
(E) IL-6 in ST: ART-successfully treated, ART-naïve, EC: elite controllers, and HS: healthy subjects. n=14 per study group. Pearson
rank correlation was used for statistical analysis.
doi: 10.1371/journal.pone.0078146.g005
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enzyme in the pyrrolnitrin biosynthesis pathway) [47]. Our
findings suggest a link between the distinctive Trp catabolism
in EC and a consistently lower FOXO3a and TDO expression
in these patients. Indeed, in EC both expression
of TDO and FOXO3a which are glucocorticoid receptor targets
are low when compared with any other HIV group or
HS.   Polymorphisms on the promoter of the TDO gene that
could affect expression and/or activity of TDO through
glucocorticoid induction may explain the ability of EC to
control oxidative stress and immuno-
metabolism changes induced by HIV [48,49]. Of note, our
results on TDO mRNA expression were obtained from PBMCs
and this may be a limitation to the study.
An association between enhanced IDO activity in DCs and
Treg induction has been previously reported in chronic hepatitis
C infection [50]. Accordingly, recent studies showed that in vitro
HIV-1 infection impairs the capacity of DCs to induce Tregs
[51]. As IDO is intracellular and not secreted, the metabolic
effects of IDO begin as inherently local signals stemming from
CTLA-4 ligation with CD80/CD86 expressed by DCs
[3,7,52,53]. Acute HIV-1 infection is associated with a large
increase in TLR signaling and IFN concentrations through
plasmacytoid DCs resulting in IDO upregulation [39]. In
addition, IL-1β, IL-6, and TNF-α, were shown to induce IDO
activity and Kyn production in vitro in the presence of LPS and
IFNγ [2,54]. The former findings are not in line with our ex vivo
observations. Indeed, we found elevated levels of IL-6,
sCD40L, IFNγ and TNF-α in ART-naïve subjects compared to
EC. However only sCD40L and TNF-α were positively
correlated with IDO enzymatic activity and IDO-1 mRNA
expression, suggesting DC-induced Trp catabolism in
association with these elevated inflammatory factors may be
important drivers of HIV-1 disease progression. In previous
studies, neopterin, an independent prognostic factor for HIV
disease outcome and immune activation was shown to
correlate Trp degradation [10,11]. Alternatively, in our study we
evaluated the correlation between Trp catabolism and IL-6
plasma levels which is the best marker of HIV-1 associated
disease progression and mortality [55,56]. We observed a
similar positive correlation of IDO activity (Kyn/Trp ratio) and
IL-6 plasma levels suggesting that Trp catabolites may be
considered as inflammation-related markers for HIV-1 disease
progression. Indeed, it has been shown that the Kyn/Trp ratio
independently predicts mortality in association with high gut
epithelial cell apoptosis in HIV-1 infection[55].
Collectively, our results favor a model where IDO-induced
Trp catabolism in association with elevated levels of TNF-α and
sCD40L has a harmful effect on Th17/Treg balance fueling
microbial translocation in HIV-1-infected patients. In contrast,
while EC displayed (1) low plasma Trp levels similar to ART-
naïve patients, they did so without elevated
immunosuppressive Kyn levels and Th17/Treg balance
disruption and (2) EC present with a dramatically low TDO
expression when compared to other study groups. Given the
immuno-metabolic role of IDO in maintaining chronic
inflammation, our results provide evidence that novel
immunotherapeutic strategies using IDO inhibitors will highly
likely help reduce immune activation while enhancing immune
control, that could in turn contribute to HIV-1 eradication.
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